Adjunctive efficacy of Bifidobacterium animalis subsp. lactis XLTG11 for functional constipation in children

Ke Chen,Zengyuan Zhou,Yang Nie,Yanmei Cao,Ping Yang,Ying Zhang,Ping Xu,Qinghua Yu,Yang Shen,Weiwei Ma,Shanshan Jin,Changqi Liu

DOI: https://doi.org/10.1007/s42770-024-01276-3

2024-02-22

Brazilian Journal of Microbiology

Abstract:Functional constipation (FC) can seriously affect the physical and mental health of children. The goal of this study is to assess the efficacy and safety of Bifidobacterium animalis subsp. lactis XLTG11 in treating FC in children through a randomized, double-blinded, placebo-controlled approach. Eligible children were randomized into either the intervention group (IG, n = 65, receiving conventional treatment with probiotics) or the control group (CG, n = 66, receiving conventional treatment without probiotics). The primary outcome measure was fecal frequency. Fecal gut microbiota analysis and PICRUSt (Phylogenetic Investigation of Communities by Reconstruction of Unobserved States) were used to predict gene family abundances based on 16S information. Over the course of treatment, the weekly frequency of feces within each group increased significantly ( F = 41.97, p < 0.001). The frequency of feces (times/week (t/w)) in the IG was significantly higher than that in the CG (3.69 ± 2.62 t/w vs.3.18 ± 1.43 t/w, 4.03 ± 2.54 t/w vs. 2.89 ± 1.39 t/w and 3.74 ± 2.36 t/w vs. 2.94 ± 1.18 t/w and 3.45 ± 1.98 vs. 3.17 ± 1.41 t/w for the 1st, 2nd, 3rd, and 4th week after intervention, respectively) ( F = 7.60, p = 0.0067). After the intervention, dominate species shifted to Bifidobacterium longum , Bifidobacterium breve , and Escherichia coli in the IG. Additionally, genes related to short-chain fatty acid (SCF) metabolism were upregulated, while methane metabolism was downregulated. Administration of XLTG11 at a dose of 1 × 10 10 CFU/day to children increased fecal frequency, induced beneficial changes in gut microbiota, and regulated SCFs and methane metabolism–related genes.

microbiology

What problem does this paper attempt to address?

The paper attempts to address the issue of evaluating the adjunctive efficacy and safety of the probiotic **Bifidobacterium animalis subsp. lactis XLTG11** in the treatment of functional constipation (FC) in children. Specifically, the study assesses the efficacy of this particular probiotic strain in treating functional constipation in children through a randomized, double-blind, placebo-controlled method.

### Background
Functional constipation (FC) is a common pediatric condition, accounting for 10% to 25% of gastroenterology cases, with 90% to 95% of childhood constipation being functional. Chronic constipation not only affects children's nutritional status and growth but also imposes economic and psychological stress on parents. The gut microbiota plays a significant role in the physiology and pathophysiology of constipation, with specific microbial metabolites such as short-chain fatty acids (SCFAs) and tryptophan metabolites playing key roles in gut function. In recent years, some randomized controlled trials have shown that certain probiotic strains have anti-constipation effects in children, leading to the recommendation of probiotic supplements as an adjunctive treatment for constipation.

### Objective
The study aims to explore the adjunctive clinical efficacy of the **Bifidobacterium animalis subsp. lactis XLTG11** strain in children with functional constipation. Specific objectives include:
1. Evaluating the adjunctive efficacy of the **XLTG11** strain in treating functional constipation in children.
2. Assessing the impact of the **XLTG11** strain on the gut microbiota.
3. Analyzing the regulatory effects of the **XLTG11** strain on short-chain fatty acids and methane metabolism-related genes.

### Methods
- **Study Design**: Multicenter, parallel randomized, controlled, double-blind clinical intervention.
- **Subjects**: Children aged 0-6 years with functional constipation.
- **Grouping**: Eligible children were randomly assigned to the intervention group (IG, n=65, receiving conventional treatment plus probiotics) and the control group (CG, n=66, receiving only conventional treatment).
- **Primary Outcome Measure**: Weekly defecation frequency.
- **Secondary Outcome Measures**: Total and average weekly Bristol stool scores, and gut microbiota analysis before and after treatment.

### Results
- **Defecation Frequency**: The weekly defecation frequency in the intervention group was significantly higher than in the control group.
- **Stool Characteristics**: The total and average weekly Bristol stool scores in the intervention group were significantly higher than in the control group.
- **Gut Microbiota**: Post-intervention, the gut microbiota diversity in the intervention group increased, with dominant species shifting to **Bifidobacterium longum**, **Bifidobacterium breve**, and **Escherichia coli**. Additionally, genes related to short-chain fatty acid metabolism were upregulated, while genes related to methane metabolism were downregulated in the intervention group compared to the control group.

### Discussion
- The **XLTG11** strain showed good adjunctive efficacy in treating functional constipation in children, consistent with previous studies using other probiotic strains.
- **Changes in Gut Microbiota**: Probiotic intervention not only increased defecation frequency but also significantly improved stool characteristics and had a positive impact on the gut microbiota.
- **Mechanism**: These changes may be related to the regulatory effects of the **XLTG11** strain on the gut microbiota, particularly on genes related to short-chain fatty acid and methane metabolism.

In conclusion, this study provides strong evidence for the adjunctive efficacy of the **Bifidobacterium animalis subsp. lactis XLTG11** strain in treating functional constipation in children, laying the foundation for further clinical applications.